

May 26, 2016
Nissan Chemical Industries, Ltd.

To whom it may concern:

Marketing Approval from European Medicines Agency for BRAVECTO™ Spot-On Solution

May 24, 2016 – MSD Animal Health (known as Merck Animal Health in the United States and Canada) announced that the European Medicine Agency has granted a marketing authorization for the new veterinary medicinal product BRAVECTO (fluralaner) Spot-On Solution for both cats and dogs. In 2014, MSD Animal Health launched BRAVECTO as a chewable tablet for dogs, which contains a new ectoparasiticide for companion animals, fluralaner invented by Nissan Chemical, and it has been sold in more than 60 countries since its introduction.

BRAVECTO Spot-On provides unique immediate and persistent tick and flea killing activity for both cats and dogs for 12 weeks following a single dose, which is longer than currently available once-monthly commercialized products.

The active substance of BRAVECTO, fluralaner belonging to the isoxazoline group possesses a new mode of action different from currently available once-monthly products, and Nissan Chemical supplies it to MSD Animal Health.

MSD Animal Health endeavors to obtain BRAVECTO Spot-On marketing authorization in the other countries including USA and Japan in addition to EU countries.

About MSD Animal Health

MSD Animal Health (Head quarter in New Jersey, the United States), the global animal health business unit of Merck & Co., Inc., who has been a global health care leader for 125 years, is present in more than 50 countries, while its products are available in some 150 markets. MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services.

BRAVECTO™ is a trademark of MSD Animal Health, Summit N.J., USA